Exponent, Inc. — Form 10-Q Summary
Period: Quarter ended April 4, 2014. The request metadata says 2013 Q1, but the filing covers the first quarter of 2014; its comparison period is the three months ended March 29, 2013. Unaudited figures are in thousands except per-share data.
Business context and financial performance
Exponent is an engineering and scientific consulting firm. It reports two operating segments: Engineering and Other Scientific, and Environmental and Health.
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Revenue | $75,962 | $72,660 | +4.5% |
| Revenue before reimbursements | $72,967 | $68,992 | +5.8% |
| Operating income | $14,094 | $10,851 | +29.9% |
| Net income | $9,154 | $7,976 | +14.8% |
| Diluted EPS | $0.66 | $0.56 | +17.9% |
| Operating margin on revenue | 18.6% | 14.9% | Up 3.7 percentage points |
| Net margin on revenue | 12.0% | 11.0% | Up 1.0 percentage point |
Revenue rose in both segments: Engineering and Other Scientific revenue was $55,827 (+4.7%), and Environmental and Health revenue was $20,135 (+4.1%). Management attributed growth mainly to higher billable hours and billing rates. Billable hours increased 3% overall to 274,000; utilization was 72%, unchanged year over year. The filing reports no debt balance; listed liabilities are operating and other obligations.
Cash flow, liquidity, and capital allocation
- Operating cash flow was negative $6,120, versus negative $5,182 a year earlier. Management said first-quarter operating cash requirements are generally higher because annual bonuses are paid.
- Investing activities provided $225, compared with $9,281, mainly reflecting fewer short-term investment maturities; capital expenditures were $915 versus $1,959.
- Financing activities used $11,580, compared with $15,192, reflecting lower stock repurchases, partly offset by higher dividends. Cash and cash equivalents declined by $17,327 to $105,621.
- Cash, cash equivalents, and short-term investments totaled $137,452 at April 4, 2014, down from $156,119 at January 3, 2014. Current assets were $249,641 and current liabilities $62,402.
- The company declared and paid a $0.25-per-share quarterly dividend, up from $0.15 in the prior-year quarter, and announced another $0.25 dividend payable June 27, 2014, subject to the stated record date. It repurchased 102,719 shares for $7.631 million during the quarter; $23.369 million remained authorized.
Management said existing liquidity and expected operating cash flows should meet operating needs, capital expenditures, commitments, repurchases, dividends, and other requirements for at least the next 12 months. Contractual commitments totaled $25.480 million, principally operating leases.
Changes, outlook, risks, and unusual items
- Net income increased 15%; diluted EPS rose faster, with management citing both higher income and the ongoing repurchase program. EBITDA was $16.643 million, or 22.8% of revenue before reimbursements, versus $14.609 million and 21.2% a year earlier. These are non-GAAP measures.
- Other income, net, declined 52.1% to $1.271 million, primarily because gains in deferred-compensation plan assets were smaller than in the prior-year quarter. The related compensation expense decreased correspondingly. Effective tax rate was 40.4%, versus 40.9%.
- Management expects some major investigations to step down from elevated activity and anticipates reduced defense technology development work because of defense-spending constraints and the U.S. drawdown in Afghanistan. It expects compensation, other operating expenses, and general and administrative expenses to rise as it selectively hires, invests in infrastructure, and expands business development.
- Risks cited include weaker demand tied to economic conditions, engagement timing, competition and pricing, lack of backlog, retaining key staff, regulation and tort reform, and claims against the company. Management provided no numerical revenue or earnings guidance.
- A lawsuit involving hiring employees from another consulting firm was in discovery, with no trial date set. The company had accrued an immaterial amount and said, after consulting counsel, it did not expect a material adverse effect; litigation outcomes remain uncertain. The filing also says there were no material legal proceedings, so the scope and characterization of that statement should be checked against the lawsuit disclosure.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting. No material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Confirm the reporting period: the filing is Q1 2014, not Q1 2013 as specified in the request metadata.
- Review the causes and sustainability of revenue and operating-margin growth, including major-investigation activity and the anticipated defense-practice slowdown.
- Assess negative first-quarter operating cash flow, working-capital movements, and the planned uses of liquidity for dividends, repurchases, and investment.
- Check the lawsuit’s status, accrued amount, and potential exposure, and reconcile its disclosure with the statement that there were no material legal proceedings.
- Monitor deferred-compensation plan assets and liabilities, which are exposed to market-value changes, and the company’s stated risks around client demand and hiring.